HanAll Biopharma009420.KS

About HanAll Biopharma

HanAll Biopharma is a Seoul-based pharmaceutical company that combines a domestic drug business with clinical-stage biologics development. Its Korean operations sell prescription medicines and eye-care products, generating cash that helps fund research. The company's most closely watched asset is an anti-FcRn antibody program targeting autoimmune conditions, which it has licensed to overseas partners for development in North America and Greater China. HanAll operates within the orbit of Daewoong Pharmaceutical, its largest shareholder, and derives revenue from a mix of domestic drug sales, licensing fees, and milestone payments tied to the progress of partnered pipeline programs.

For foreign investors, HanAll is effectively a hybrid of a stable Korean pharmaceutical business and a biotech option, and that mix defines the risk profile. Value hinges on clinical and regulatory outcomes at overseas licensees rather than on factors HanAll directly controls, an unusual dependency among Korean mid-cap drug names. The Daewoong affiliation shapes board composition and strategic direction. Licensing income is lumpy by nature, making reported earnings uneven, while the domestic drug franchise is exposed to Korean government drug-pricing policy.

HanAll's corporate story begins in 1973, when the company was founded as Hanall Pharmaceutical, a conventional Korean drugmaker producing prescription medicines. For roughly its first four decades it operated independently, gradually shifting resources from generics toward antibody research and adopting the Biopharma identity to signal that reorientation. The decisive structural change came in 2015, when Daewoong Pharmaceutical purchased a controlling interest, ending HanAll's standalone era while preserving its separate stock listing, brand, and research organization. Since that transaction, HanAll has functioned as the biologics-focused member of the Daewoong pharmaceutical family, keeping its own laboratories, executive team, and clinical pipeline while coordinating research priorities with its parent.

The business model pairs a self-funding domestic operation with an outsourced global development engine. In Korea, HanAll manufactures and markets prescription drugs and eye-care products through established hospital and pharmacy channels, producing dependable cash flow. Internationally, it monetizes its antibody science by licensing programs to regional partners, who pay upfront fees on signing, milestone payments as trials advance, and royalties if products reach the market, while bearing the trial costs themselves. This structure lets a mid-sized Korean firm pursue global autoimmune indications without funding late-stage studies alone. Competitively, HanAll is among the few Korean developers working in the FcRn field, where larger overseas biotechs set the clinical benchmark.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full DART-based report on HanAll Biopharma →